Risultati per: Standard di cura nel diabete 2024

Con IA 2 settimane lavoro l’anno risparmiate per medici famiglia

Con IA 2 settimane lavoro l’anno risparmiate per medici famiglia

Conferenza Icar, ‘attenzione al dialogo medico-paziente’

We sincerely thank the 797 peer reviewers who completed manuscript reviews for JAMA Dermatology in 2024.

We sincerely thank the 2895 peer reviewers who completed manuscript reviews for JAMA in 2024.

2025 has already been a dynamic year for science, medicine, and public health. In response to the uncertainty and ongoing concerns, JAMA editors recently reaffirmed our commitment to our core mission: to publish science, education, and perspectives that shape the practice of medicine and public health. The groundwork we laid in 2024 will hold us in good stead during this time as we continue to meet the needs of our authors and readers worldwide.

Diabetologi, impatto di 14miliardi anno,pari a10% costi sanitari

Nella clinica dermatologica Azienda ospedaliera delle Marche

We sincerely thank the 581 peer reviewers who completed manuscript reviews for JAMA Oncology in 2024.

Neglet e l’afasia tra principali problemi lungo termine malattia

Esperto Sidp, se gengive dolenti +54% probabilità di soffrirne

We sincerely thank the 651 peer reviewers who completed manuscript reviews for JAMA Psychiatry in 2024.

Tra i giovani pazienti cresce l’uso di microinfusori di insulina

Idrocefalo normoteso, malattia curabile ma poco nota. Possibili fino a 35 miliardi di euro di risparmio in un anno per il Servizio sanitario nazionale

Introduction
Persistent acute kidney injury (AKI) is associated with an increased morbidity and mortality. In patients with an already established AKI, the new urinary biomarker C-C motif chemokine ligand 14 (CCL14) can predict a persistent AKI. However, it is still unknown whether the implementation of nephroprotective measures in patients with an already established moderate/severe AKI can positively influence the trajectory of AKI and patients’ outcome.

Methods and analysis
The PrevProgAKI trial is a randomised, controlled, single-centre trial designed to evaluate the effectiveness of nephroprotective measures in patients with established moderate/severe AKI. We aim to enrol 480 patients with moderate or severe AKI (Kidney Disease: Imroving Global Outcomes, KDIGO, stage 2 or 3) within 72 hours of major surgery. Eligible patients will be randomised to receive either standard of care (control group) or an extended therapeutic strategy that consists of different supportive measures (intervention group). The randomisation will be stratified by urinary CCL14 results (CCL14

Annals of Internal Medicine, Ahead of Print.